Invectys awarded « 2019 best project – start-up category » by the MATWIN international Board
Invectys exploits two complementary technological platforms: telomerase-based vaccines and HLA-G checkpoint inhibitors and CAR T cells. MATWIN’s Board selected Invectys on the basis of its HLA-G platform.
Among the nine projects interviewed this year, the CAR-Go project presented by Invectys was awarded “Best project – start-up category” by the MATWIN International Board.
To view the press release click here -> press release
